BPA Call 36C25921A0036-36C25925N0118

Award Date 5/1/25
Potential Completion Date 4/30/26
Potential Value $53K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Salt Lake City, UT 84148, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc., to provide its Prolaris prostate cancer genetic testing services to the U.S. Department of Veterans Affairs (VA). The contract, with a ceiling value of $6,000.00, is a firm fixed-price delivery order that supports disease risk stratification and treatment planning for veterans served by the VA healthcare system, including the Salt Lake City VA Medical Center. Myriad Genetics Inc. has been...
This federal contract award to Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc., is for a Firm Fixed Price Purchase Order of $7,946.32 to provide MYRIAD GENETIC TESTING services. The contract, awarded by the Defense Health Agency, has an ultimate completion date of February 25, 2017. Myriad Genetic Laboratories Inc. is a for-profit company that specializes in genetic testing and precision medicine services. The primary service provided under this contract is the Prolaris...
This federal contract award from the Department of Veterans Affairs (VA) Veterans Health Administration was granted to Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc., to provide Prolaris prostate cancer testing services. The firm fixed price contract, valued at $14,994.00, is a Blanket Purchase Agreement (BPA) call to support disease risk stratification and treatment planning for veterans served by the VA's Veterans Integrated Service Network (VISN) 19 in Salt Lake...
This is a federal contract award from the Department of Veterans Affairs (VA) to Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc. The contract is for the provision of Prolaris prostate cancer testing services to the VA's Salt Lake City VA Medical Center. The contract is a Blanket Purchase Agreement (BPA) call with a ceiling value of $2,499. The contract has no set-aside designation. This BPA is part of a larger Indefinite Delivery Vehicle (IDV) awarded by the VA's...
This federal contract award is for the delivery of Prolaris genetic testing services to the U.S. Department of Veterans Affairs (VA). The prime contractor is Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc. that specializes in personalized medicine and genetic testing. The contract was awarded by the VA's Veterans Integrated Service Network 12 (VISN 12) and the VA Salt Lake City Health Care System. It includes two Indefinite Delivery Vehicles (IDVs) - an Indefinite Delivery...
This $122,672 federal contract was awarded by the Department of Veterans Affairs (VA) to Myriad Genetic Laboratories Inc., a for-profit organization specializing in personalized medicine and genetic testing services. The contract is for the delivery of Prolaris prostate cancer testing services, which analyze genetic information to determine disease progression risks and support clinical treatment decisions. The contract was competitively awarded without a set-aside designation, and is structured...
This is a firm fixed price delivery order awarded to Myriad Genetic Laboratories Inc., a leading genetic testing and precision medicine company, by the Department of Veterans Affairs (VA) Veterans Health Administration. The $10,982 contract is for the provision of Prolaris prostate cancer testing services to support disease risk stratification and treatment planning for veterans served by the VA's Veterans Integrated Service Network 12. Myriad Genetic Laboratories previously held a $149,600...
This is a firm-fixed-price contract awarded by the Medical Command (MEDCOM) of the U.S. Army to Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc. The $95,000.00 contract is for the provision of various genetic testing services, with a focus on Prolaris prostate cancer testing. The contract is a Blanket Purchase Agreement (BPA) call, allowing the Department of Veterans Affairs (VA) to efficiently procure Myriad's specialized genetic testing services across multiple regions....
This federal contract award to Myriad Genetics Inc. is for a Blanket Purchase Agreement (BPA) call valued at $100,000 to provide genetic testing services related to cancer diagnostics and risk assessment. The contract was awarded by the Defense Health Agency, a component of the Department of Defense, to deliver Myriad's Prolaris quantitative PCR testing on prostate biopsy samples. The Prolaris test helps assess tumor aggressiveness and guide treatment approaches for prostate cancer patients....
This federal contract award was made by the Defense Health Agency (DHA) to Myriad Genetics Inc., a molecular diagnostic company headquartered in Salt Lake City, Utah. The $100,000.00 firm-fixed-price contract is for MYRIAD GENETIC TESTING services, specifically the company's ProLaris testing for prostate cancer. The contract has no set-aside designation, indicating open competition. This award is part of Myriad Genetics Inc.'s ongoing work providing specialized genetic testing services,...
  • 36C25921A0036
    Blanket Purchase Agreement
  • 36C25921A0036-36C25925N0118
    BPA Call

This is a federal contract award to Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc., a for-profit organization specializing in personalized medicine and genetic testing services. The contract, awarded by the Department of Veterans Affairs (VA), is for the provision of Prolaris prostate cancer testing services for the VA's Salt Lake City Medical Center. The contract is a Blanket Purchase Agreement (BPA) call with a firm fixed price of $52,954.00 and a performance period extending through April 30, 2026. The contract does not have a set-aside designation, indicating Myriad competed directly in the open market. Myriad holds two primary federal contract Indefinite Delivery Vehicles with the VA, which enable the systematic procurement of its specialized genetic testing services across multiple regions to support disease risk stratification and treatment planning for veteran patients.

Generated 5/1/25, 10:02 AM